Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gwen Nichols

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
The Oncologist|July 1, 2008
Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled studyDavid Gordon, Gwen Nichols, Ali Ben-Jacob, et al.
Cancer Cell|December 13, 2017
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic EfficacyRongqing Pan, Vivian Ruvolo, Hong Mu, et al.
Cancer Chemotherapy and Pharmacology|January 26, 2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumorsJohn Nemunaitis, Annie Young, Samuel Ejadi, et al.
Molecular Cancer Therapeutics|October 16, 2013
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDACRichard D Dinnen, Yuehua Mao, Wanglong Qiu, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2015
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumorsAmita Patnaik, Anthony Tolcher, Murali Beeram, et al.
Biomedicines|January 21, 2023
C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In VivoRobert L Fine, Yuehua Mao, Richard Dinnen, et al.
Biomedicines|February 25, 2023
Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In VivoRobert L Fine, Yuehua Mao, Dario Garcia-Carracedo, et al.
Molecular Cancer Therapeutics|January 25, 2006
Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptidePatrick B Senatus, Yin Li, Christopher Mandigo, et al.
Leukemia & Lymphoma|April 12, 2003
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemiaDavid G Savage, Neil S Cohen, Charles S Hesdorffer, et al.
American Heart Journal|January 19, 2024
Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tankKonstantin A Krychtiuk, Tomas Lg Andersson, Ulrike Bodesheim, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
The Oncologist|July 1, 2008
Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled studyDavid Gordon, Gwen Nichols, Ali Ben-Jacob, et al.
Cancer Cell|December 13, 2017
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic EfficacyRongqing Pan, Vivian Ruvolo, Hong Mu, et al.
Cancer Chemotherapy and Pharmacology|January 26, 2018
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumorsJohn Nemunaitis, Annie Young, Samuel Ejadi, et al.
Molecular Cancer Therapeutics|October 16, 2013
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDACRichard D Dinnen, Yuehua Mao, Wanglong Qiu, et al.
Cancer Chemotherapy and Pharmacology|July 27, 2015
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumorsAmita Patnaik, Anthony Tolcher, Murali Beeram, et al.
Biomedicines|January 21, 2023
C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In VivoRobert L Fine, Yuehua Mao, Richard Dinnen, et al.
Biomedicines|February 25, 2023
Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In VivoRobert L Fine, Yuehua Mao, Dario Garcia-Carracedo, et al.
Molecular Cancer Therapeutics|January 25, 2006
Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptidePatrick B Senatus, Yin Li, Christopher Mandigo, et al.
Leukemia & Lymphoma|April 12, 2003
Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemiaDavid G Savage, Neil S Cohen, Charles S Hesdorffer, et al.
American Heart Journal|January 19, 2024
Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tankKonstantin A Krychtiuk, Tomas Lg Andersson, Ulrike Bodesheim, et al.
Pageof 2